Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 18/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2809726 | 0.93 | PLA2G4A (0.61) | PLA2G4A | |
| SCHEMBL2806139 | 0.85 | PLA2G4A (0.79) | PLA2G4A | |
| SCHEMBL13127476 | 0.85 | PLA2G4A (0.79) | PLA2G4A | |
| SCHEMBL2804268 | 0.85 | PLA2G4A (0.73) | PLA2G4A | |
| SCHEMBL2807308 | 0.85 | MAPT (0.44) | PLA2G4AMAPTSMN1; SMN2 | |
| SCHEMBL2835991 | 0.84 | PLA2G4A (0.78) | PLA2G4A | |
| SCHEMBL2806777 | 0.80 | PLA2G4A (0.52) | PLA2G4A | |
| SCHEMBL2806882 | 0.78 | PLA2G4A (0.45) | PLA2G4AMAPTSMN1; SMN2 | |
| SCHEMBL13127477 | 0.78 | PLA2G4A (0.79) | PLA2G4A | |
| SCHEMBL2804469 | 0.78 | PLA2G4A (0.73) | PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240718-A1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVE, SUITABLE FOR INHIBITING PHOSPHOLIPASE A2 | WESTFALISCHE WILHELMS UNIVERSITÄT MÜNSTER (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240718-A1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVE, SUITABLE FOR INHIBITING PHOSPHOLIPASE A2 | PLD2, PLA2G1B, PLA2G4A | PLA2G4A 3/4885GAA 1064/4885NPC1 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.